Nasdaq:AMPH
Amphastar Pharmaceuticals, Inc.
A global specialty generic pharmaceutical manufacturer capitalizing on bioequivalent drug development and advanced formulation technologies.
Key Metrics
Investment Thesis
Bull Case
Investors may view Amphastar as an attractive opportunity due to its dominant market positions in high-volume generic therapeutic areas that offer predictable revenue streams. The company's proprietary manufacturing technologies create a significant barrier to entry for competitors, protecting margins against new entrants. Strong balance sheet liquidity provides flexibility to fund R&D initiatives and capitalize on upcoming patent expirations of major brand-name drugs.
Bear Case
The stock faces headwinds from recent revenue decline and a sharp drop in net income which could signal margin compression or one-time charges. Significant debt levels with $619.7M in long-term debt pose interest rate sensitivity risks that could impact future profitability. The generic pharmaceutical sector is increasingly crowded, threatening the company's ability to sustain growth rates seen in previous years.
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals is a leading global specialty pharmaceutical manufacturer focused on developing and commercializing generic drugs that are bioequivalent to brand-name products. The company serves major healthcare markets worldwide with a robust portfolio of high-volume formulations including oncology, autoimmune, cardiovascular, and central nervous system therapies. Amphastar leverages its proprietary manufacturing technologies and extensive supply chain capabilities to deliver cost-effective treatments for patients globally.
Analysis
Management Discussion
Amphastar reported revenue of $719.9M in the latest period, reflecting a slight contraction from 2024's $732.0M despite a strong overall growth trajectory over the past three years. Net income decreased to $98.1M compared to $159.5M in 2024, driven by elevated operating expenses and interest costs against a backdrop of significant capital expenditures totaling $34.9M. The company maintains a healthy cash position with $170.4M in ending cash and equivalents, though it continues to service substantial long-term debt obligations.
Industry Overview
The global generic pharmaceutical industry is characterized by intense competition, regulatory scrutiny, and a reliance on timely patent expirations of brand-name drugs. Companies must balance rapid product development with stringent quality standards to maintain market share against established competitors. The sector offers stable long-term growth driven by the universal need for affordable healthcare solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $499.0M | $644.4M | $732.0M | $719.9M |
| Cost of Revenue | $250.1M | $293.3M | $358.1M | $363.8M |
| Gross Profit | $248.9M | $351.1M | $373.9M | $356.1M |
| Operating Expenses | $141.4M | $154.1M | $168.4M | $215.7M |
| Operating Income | $107.5M | $197.0M | $205.4M | $140.4M |
| R&D | $74.8M | $73.7M | $73.9M | $85.8M |
| G&A | $45.1M | $51.5M | $56.7M | $85.9M |
| Marketing | $21.5M | $28.9M | $37.8M | $43.9M |
| Stock-Based Comp | $17.9M | $20.2M | $24.4M | $27.3M |
| D&A | $12.6M | $25.7M | — | — |
| Depreciation | $23.8M | $25.2M | $28.2M | $31.6M |
| Amortization | $1.4M | $12.8M | $24.7M | $25.0M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $8.5M | $-25.6M | $-15.7M | $-16.8M |
| Interest Expense | $1.8M | $27.2M | — | — |
| Interest Income | $1.3M | $5.5M | $10.6M | $8.7M |
| Pre-Tax Income | $116.0M | $171.4M | $189.8M | $123.6M |
| Income Tax | $23.5M | $31.8M | $29.7M | $25.5M |
| Continuing Ops | $92.6M | $139.5M | $160.1M | $98.1M |
| Discontinued Ops | $-1.2M | $-2.0M | $-573.0K | $0 |
| Net Income | $91.4M | $137.5M | $159.5M | $98.1M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $91.4M | $137.5M | $159.5M | $98.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $378.3M | $489.6M | $534.1M | $636.0M |
| Cash & Equivalents | $156.1M | $144.3M | $151.6M | $170.2M |
| Marketable Securities | $19.7M | $112.5M | $70.0M | $112.6M |
| Accounts Receivable | $88.8M | $114.9M | $136.3M | $143.6M |
| Inventory | $103.6M | $105.8M | $153.7M | $176.9M |
| Prepaid Expenses | $7.6M | $9.1M | $18.2M | $13.2M |
| Other Current Assets | $2.6M | $3.0M | $4.2M | $19.6M |
| Long-Term Assets | $363.7M | $1.02B | $1.04B | $993.3M |
| PP&E (Net) | $238.3M | $282.7M | $297.3M | $310.6M |
| Goodwill | $3.1M | $3.2M | $3.0M | $3.4M |
| Operating Leases | $25.6M | $32.3M | $46.9M | $42.9M |
| LT Investments | — | $14.7M | $11.0M | — |
| Other LT Assets | $94.3M | $690.3M | $685.1M | $636.4M |
| Total Assets | $742.0M | $1.51B | $1.58B | $1.63B |
| Current Liabilities | $94.9M | $225.4M | $173.8M | $158.2M |
| Accounts Payable | $20.5M | $25.4M | $30.5M | $32.6M |
| Current Leases | $3.0M | $3.9M | $6.8M | $7.9M |
| Taxes Payable | $4.6M | $1.6M | $9.7M | $239.0K |
| Other Current Liab | $3.0M | $126.5M | $234.0K | $1.6M |
| Long-Term Liabilities | $118.5M | $648.1M | $671.4M | $682.3M |
| Long-Term Debt | $76.6M | $603.2M | $613.5M | $619.7M |
| LT Operating Leases | $23.7M | $29.7M | $41.9M | $37.7M |
| Other LT Liab | $10.9M | $9.1M | $9.0M | $19.0M |
| Total Liabilities | $213.3M | $873.5M | $845.2M | $840.5M |
| Shareholders' Equity | $528.7M | $639.4M | $732.3M | $788.8M |
| Paid-In Capital | $455.1M | $486.1M | $505.4M | $535.4M |
| Retained Earnings | $271.7M | $409.3M | $568.8M | $666.9M |
| AOCI | $-8.6M | $-8.5M | $-9.2M | $-5.3M |
| Treasury Stock | $189.5M | $247.4M | $332.7M | $408.1M |
| Total L&E | $742.0M | $1.51B | $1.58B | $1.63B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $91.4M | $137.5M | $159.5M | $98.1M |
| Non-Cash Adjustments | $-41.6M | $-10.4M | $-108.8M | $60.3M |
| Working Capital Changes | $39.4M | $56.4M | $162.6M | $-2.3M |
| Cash from Operations | $89.2M | $183.5M | $213.4M | $156.1M |
| Capital Expenditures | $24.0M | $38.2M | $41.0M | $34.9M |
| Cash from Investing | $-32.8M | $-649.1M | $-124.9M | $-70.3M |
| Debt Issuances | — | $845.0M | — | — |
| Debt Repayments | $1.8M | $318.7M | $8.3M | $223.0K |
| Share Buybacks | $39.9M | $58.1M | $85.5M | $75.6M |
| Cash from Financing | $-26.4M | $454.1M | $-81.0M | $-67.4M |
| FX Effect | $-220.0K | $-282.0K | $-190.0K | $210.0K |
| Net Change in Cash | $29.7M | $-11.8M | $7.3M | $18.6M |
| Beginning Cash | $126.6M | $156.3M | $144.5M | $151.8M |
| Ending Cash | $156.3M | $144.5M | $151.8M | $170.4M |
Frequently Asked Questions
How does Amphastar Pharmaceuticals, Inc. make money?
The company's revenue streams are derived primarily from the sale of generic pharmaceutical products across high-volume therapeutic categories such as oncology, autoimmune diseases, cardiovascular health, and central nervous system disorders. Additional revenue is generated through contract manufacturing services and licensing agreements that leverage its specialized production capabilities.
What are the main risks for AMPH?
Regulatory challenges in key markets could delay product approvals or impact pricing structures for generic medications. The company faces significant patent cliff risks as brand-name drugs lose exclusivity protection, potentially leading to rapid market erosion if the company cannot maintain its manufacturing lead time. Intense competition from other generic manufacturers may compress profit margins on high-volume products. Macroeconomic headwinds and supply chain disruptions could impact raw material costs and operational efficiency.
What is AMPH's competitive advantage?
Amphastar possesses a distinct competitive moat through its proprietary advanced manufacturing technologies that enable the development of complex generic formulations difficult for competitors to replicate. The company benefits from a diverse global supply chain network and established regulatory relationships that accelerate market entry for new products. Its strategic focus on high-volume, high-growth therapeutic areas provides consistent cash flow generation and scalability.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.